NEW YORK, April 2, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative treatments for unmet medical needs, today announced ...
Hoth Therapeutics filed patents to address skin toxicities from cancer therapies, focusing on HT-001's neurogenic and inflammatory pathway targeting. The patents aim to secure intellectual property ...
Hoth continues to advance HT-001 in its Phase 2 CLEER-001 clinical trial targeting EGFR-inhibitor–associated rash, a significant unmet need in oncology supportive care. Recent progress includes: ...
Hoth Therapeutics Inc. HOTH on Tuesday said it plans to rebrand as Rocket One Inc. and restructure its operations to focus on artificial intelligence infrastructure, semiconductor technologies, and ...
Hosted on MSN
Why is HOTH stock up 70% after-hours today?
・HT-VA outperformed Danish drug Novo Nordisk’s blockbuster semaglutide drug in key gene expression markers tied to liver fat regulation, the company said. ・The company is now looking to advance the ...
Hoth Therapeutics Inc HOTH shares were roaring higher Monday after the biopharma announced its foray into COVID-19 vaccine development, joining a host of companies engaged in research for a ...
Shares of micro-cap Hoth Therapeutics (NASDAQ:HOTH) on Tuesday more than doubled in value post the opening bell, after the biopharmaceutical firm announced positive preclinical results for its ...
NEW YORK, April 1, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results